Innovations in Psychedelic Treatments

This chapter explores groundbreaking advancements in treating treatment-resistant depression using new formulations like oral DMT films, providing a viable alternative to intranasal methods. It examines the promising results of initial clinical trials and highlights a novel enantiomer of MDMA aimed at addressing social anxiety disorder, especially in the aftermath of COVID-19. The discussion also covers the evolving landscape of the psychedelic medicine industry, regulatory support, and recent investments signaling confidence in future developments.